Good morning. Demand for abortion pills could rise if the U.S. Supreme Court overturns Roe v. Wade. We’ve got a snapshot of some of the key questions about medication abortion and efforts to restrict the practice. Justice Samuel Alito, whose draft opinion striking down Roe was leaked this week, won’t appear at a judicial conference set to begin in Nashville today. Plus, a new report shows law firm office leasing volume dipped in the first quarter; Netflix just got hit with a shareholder lawsuit over the company’s subscriber slump; and a Texas pastor is suing Kayne West for alleged copyright infringement. This week is flying by. Let’s dive in.
Our colleague Dan Brillman is co-writing The Daily Docket while Diana Novak Jones is on parental leave. Were you forwarded this email? Subscribe here.
|
A new report by commercial real estate brokerage Savills reveals that law firm leasing volume was down in the first quarter of 2022 to 1.1 million square feet from more than 1.5 million in the previous two quarters. The report tracked law firm leases of over 20,000 square feet, and shows that what had appeared to be a rebound in law firm leasing activity in the third quarter of last year, after diminished activity due to the COVID-19 pandemic, has not lasted, Sara Merken reports.
No law firms signed a lease for over 100,000 square feet in Q1, and there may be fewer leases that cross that line going forward, according to the report. The dip comes as law firms have had to reconsider space and amenity needs in the wake of the pandemic. Many are bringing lawyers and staff back to the office this spring, but on a hybrid basis. Law firms rethinking space appear to be favoring relocating offices over renewing leases. In the first quarter, 66% of firm leases signed were relocations by square footage. "Firms are seeking "high-quality space with amenities," so they can "earn their employees' commute," said the report's author Devon Munos. |
|
|
| Drive business value
with Practical Law
|
Navigate a fast-changing business environment with expert resources created by over 300 seasoned attorney editors. |
|
|
Drive business value with Practical Law
|
Navigate a fast-changing business environment with expert resources created by over 300 seasoned attorney editors. Be the modern general counsel your company needs with our time-saving content and tools, so you can get up to speed quickly and advise with confidence. |
|
|
If the U.S. Supreme Court reverses its landmark 1973 Roe v. Wade decision guaranteeing abortion rights nationwide, demand for abortion pills, which can be prescribed through online telemedicine visits, are predicted to spike. Christie Pitney, the chief executive of a Washington D.C. telehealth practice that works with non-profit Aid Access, said the number of women requesting prescriptions for abortion pills, or information about their use, through the group's website has tripled since Justice Alito’s draft opinion was leaked on Monday.
Medication abortions, which involve taking a drug called mifepristone, followed by a second one called misoprostol, to end a pregnancy, have become a target of anti-abortion politicians and activists. At least 116 measures restricting the practice have been introduced just this year, according to the Guttmacher Institute, following a move by the FDA late last year eliminating a requirement that abortion pills be dispensed in person. That allowed patients to consult with healthcare providers via telemedicine appointments and receive the pills by mail, increasing access to abortion for patients living in remote areas and those unable to get to clinics for other reasons.
If the Supreme Court overturns Roe, conservative states are poised to ban or sharply restrict abortion altogether, including 13 with so-called "trigger laws" that would take effect immediately or soon after the court acts. They would apply to medication abortions. Reuters' Brendan Pierson and Nate Raymond look at the laws surrounding medication abortions and how states could end up at odds over their legality.
|
-
U.S. Supreme Court Justice Samuel Alito is no longer scheduled to appear at the start of today’s 5th Circuit judicial conference in Nashville, days after his draft majority decision striking down Roe v. Wade was leaked to the news media. Alito had been set to appear at the gathering of judges from the appeals court and federal benches in Louisiana, Mississippi and Texas. (Reuters)
-
Crowell can’t depose former Walgreens Boots Alliance chief legal officer Marco Pagni in an ethics lawsuit the retail pharmacy brought against the law firm last year. Crowell has denied claims from former client Walgreens that its positions against the company in court and arbitration mark a conflict of interest. (Reuters)
-
Ballard Spahr said Minneapolis-based partner Peter Michaud was elected as the first chair to serve outside of the firm’s Philadelphia home base. He will take the position in December 2023, succeeding Mark Stewart. (Reuters)
|
That’s the number of subscribers Netflix lost in the first quarter, well short of its forecast of adding 2.5 million. The streaming service was hit with a shareholder lawsuit in San Francisco federal court accusing it of misleading the market about its ability to keep adding subscribers. Los Angeles firm Glancy Prongay & Murray represents the plaintiff, a Texas-based investment trust. A Netflix spokesperson did not immediately respond to a request for comment. Read more about the case, and what Netflix attributed for the quarterly decline.
|
The 9th Circuit refused on Monday to reconsider a first-of-its-kind decision allowing an investor who bought 30,000 shares of Slack in a 2019 “direct listing” to move ahead with Securities Act claims, even though he couldn’t prove that his shares were registered under an allegedly misleading offering statement. Slack and its friends in the business lobby couldn’t persuade the 9th Circuit that the decision by a three-judge panel was wrong as a matter of law and policy, curtailing a route to the public markets that’s cheaper and easier than traditional IPOs. Now, Alison Frankel reports, the company says it’s going to try to sell that argument to the Supreme Court.
|
Video: Carbon capture and storage development outpacing regulations |
Financial incentives and climate change pressure are fast-tracking proposals for the permanent capture and storage of carbon dioxide, but this new use of an old technology presents some legal novelties. Watch the video from Reuters video journalist Alex Cohen.
|
"Sometimes there can be things that our eyebrows jump off our heads because it was so shocking that it was done but it might not be a violation of law."
—U.S. District Judge Beth Labson Freeman commenting on a fraud case involving Ozy Media's co-founder impersonating a YouTube executive on a call with Goldman Sachs, which was weighing a $40 million investment in the company. Though Goldman eventually declined to invest, Ozy was sued by investor LifeLine Legacy Holdings who put $2 million in Ozy. Freeman dismissed the suit but allowed LifeLine to amend its original complaint. Read more about Freeman’s ruling in the case.
|
Reporter's Notebook: Fight over drug discounts for safety net providers quietly picks up steam |
Reuters health care and product liability litigation reporter Brendan Pierson on a legal fight over a key drug discount program
Skyrocketing drug prices have been a major issue in U.S. politics for years. High-profile lawsuits and Congressional hearings have focused on the tactics drugmakers use to maintain their patent protection and market share, and on the role of pharmacy benefit managers, accused by critics of driving prices up for their own benefit.
Largely outside the spotlight, however, a legal battle has been building over a drug discount program that the federal government and the American Hospital Association say is crucial for some of the nation's most vulnerable patients. The so-called 340B program, established in 1992, requires drugmakers to sell prescription drugs at discounted prices to providers that serve low-income communities, like "safety net" hospitals and community health centers committed to treating uninsured patients.
Many such providers contract with third-party pharmacies to dispense drugs. But beginning in mid-2020, major drugmakers — including Johnson & Johnson, Sanofi-Aventis, Novo Nordisk, AstraZeneca and Eli Lilly — abruptly announced they would either end or significantly limit 340B discounts for drugs dispensed through third-party pharmacies.
The drugmakers have said that the use of third-party pharmacies increases the risk of fraud and drug diversion. The shift has triggered lawsuits from the federal government. Results have been mixed, but so far, drugmakers have the upper hand, prevailing in a majority of cases in district courts. An appeal of several cases is now pending in the D.C. Circuit. If the litigation continues on its present course, and Congress doesn't intervene, safety net healthcare providers around the country could find themselves financially squeezed.
|
-
The 1st Circuit will decide whether to give students of University of Massachusetts, Lowell another chance to challenge the school’s requirement that they be fully vaccinated against COVID-19 in order to return to campus. In August, U.S. District Judge Denise Casper in Boston dismissed a lawsuit filed by two UMass students. Ryan McLane of McLane & McLane will argue for the students and will face Assistant Attorney General Richard Weitzel. Hundreds of colleges and law schools implemented COVID-19 vaccine mandates for students. The U.S. Supreme Court last year declined to stop Indiana University’s coronavirus vaccination requirement.
-
Borrowers suing debt collector Transworld Systems and two student loan trusts for allegedly seeking to collect on invalid debt in court will urge U.S. Magistrate Judge Barbara Moses in Manhattan to certify their class action. Gregory Frank of Frank LLP represents the plaintiffs; James Schultz of Sessions, Israel & Shartle is representing Transworld; and Gregory Casamento of Locke Lord is defending the student loan trusts.
-
A federal judge will consider whether to block enforcement of a new law in Alabama that would criminalize gender-affirming healthcare for transgender youth, with a threat of 10 years in prison for medical providers. U.S. District Judge Liles Burke in Montgomery, Alabama, has set aside up to two days for hearings on whether to issue a preliminary injunction barring enforcement of the Republican-backed law at the request of parents and medical providers represented by Lightfoot, Franklin & White, King & Spalding, GLBTQ Legal Advocates & Defenders and other groups. The law is set to take effect on May 8.
Court calendars are subject to last-minute docket changes.
|
-
The Rhode Island Supreme Court upheld a state law guaranteeing its citizens' right to abortion, just as reproductive rights at the national level appear to be in jeopardy. The court rejected a lawsuit by several individuals and anti-abortion group Servants of Christ for Life challenging a 2019 law that effectively secured rights set out in Roe v. Wade. (Reuters)
-
A Texas pastor is suing rapper Kanye West and label UMG for copyright infringement. David Paul Moten's complaint in Dallas federal court accuses West of using a recording of Moten's sermon without permission in the 2021 song "Come to Life." Moten is represented by Brandon Smith of Dallas-based Smith & Smith. (Reuters)
-
Intuit has agreed to pay $141 million in restitution to settle claims by all 50 states and Washington, D.C., that it tricked millions of customers into buying online TurboTax products that the company deceptively advertised as "free." The company did not admit wrongdoing. (Reuters)
-
Manhattan U.S. District Judge Paul Gardephe said he saw no reason to rule quickly in favor of JPMorgan as the bank sues Tesla over Elon Musk's 2018 tweet that he might take the electric car company private. JPMorgan sued for $162.2 million in November 2021, saying Tesla breached a contract related to stock warrants it sold to the bank, and which JPMorgan believes became more valuable because of Musk's now-notorious tweet. Gardephe said he was unlikely to rule for JPMorgan without more evidence about whether the bank acted in good faith. (Reuters)
-
The 1961 ballad ‘Can't Help Falling in Love’ has been recorded by hundreds of artists, but became a smash hit for Elvis Presley. The daughter and grandson of Hugo Peretti, who co-wrote the song, cannot recover rights from Authentic Brands Group under copyright law, the 2nd Circuit ruled. The appeals court said that the rights Valentina Peretti Acuti and Paul Reitnauer argued they were entitled to did not exist when Peretti and his family sold them. (Reuters)
|
-
BakerHostetler has added two partners to its business practice group. Elise Schuller Barajas joins the Dallas office from Gray Reed, and Brian Mulcahy joins the firm’s Chicago office from Jones Day. (Reuters)
- Veteran dealmaker Roger Barron left his post as Paul Hastings’ global M&A vice chair earlier this year to join Eversheds Sutherland in London as a senior advisor on a two-year contract. (Reuters)
-
Reed Smith said Francisco Rodriguez and Sandra Millor joined its global commercial disputes practice in Miami as partners. Rodriguez and Millor join the firm from Akerman. (Reed Smith)
-
Brown Rudnick brought on Aaron Lang in New York as a partner in the firm’s litigation and arbitration practice. Lang arrives at the firm from Cadwalader. (Brown Rudnick)
-
Gibson Dunn said Sydney Scott joined the firm as a commercial partner in Houston. Scott formerly was at Smyser Kaplan & Veselka. (Gibson Dunn)
-
Seyfarth added corporate partner Arnold Brown in San Francisco from Schwabe, Williamson & Wyatt. Brown focuses on corporate governance and commercial transactions. (Seyfarth)
|
One of new PTO Director Kathi Vidal’s first initiatives will be increasing transparency in the “director review” procedure that was set up in response to the U.S. Supreme Court’s decision in United States v. Arthrex, write David McCombs, Eugene Goryunov and Jonathan Bowser of Haynes Boone. The process allows the director, acting on her own initiative or at the request of a party, to review a final written decision of the Patent Trial and Appeal Board. The PTO now will seek public comment about the process. Learn more about the issues that might warrant the director’s review.
|
| |
Copyright © 2022 Thomson Reuters. All rights reserved. 610 Opperman Drive, Eagan, MN 55123
Want to change how you receive these emails? You can unsubscribe from this list here. |
|
|
|